Suggestions
Renaud VAILLANT
Board member and managing director of innovative companies
Renaud VAILLANT is an experienced executive and entrepreneur in the biotechnology industry, currently serving as the Founder & President of Alaya.bio.14 Here's an overview of his background and current roles:
Professional Experience
Current Positions:
- Founder & President at Alaya.bio (since July 2022)1
- President at HONING BIOSCIENCES (since July 2022)1
- Managing Director at Deep Blue Consulting (since July 2006)1
- Co-founder & strategic advisor at Mooncard (since February 2016)1
Previous Roles:
- VP Business Development & Managing Director of Ixaka France (June 2020 - November 2021)1
- CEO & Board Member at THERAVECTYS (September 2010 - October 2015)1
Expertise and Focus
Renaud VAILLANT is passionate about innovation, disruptive technologies, and patient outcomes in the biotechnology sector.1 His expertise includes:
- Guiding therapeutic products from inception to proof-of-concept and clinical trials
- Cross-sector knowledge in various therapeutic areas (infectious diseases, oncology, genetic diseases)
- Corporate strategy and deal-making
- Business development and financial expertise in biotechnology
Current Work at Alaya.bio
At Alaya.bio, VAILLANT is leading the development of a novel polymeric delivery platform designed to precisely target and reprogram cells in situ.2 The company's focus is on simplifying the development, manufacturing, and administration of CAR-T cell therapies.2
Education
Renaud VAILLANT received his education from Ecole centrale de Paris.1
Recent Developments
In July 2024, Alaya.bio entered into a collaboration agreement with Nona Biosciences to advance CAR-T cell therapy.23 This partnership aims to combine Nona's antibody discovery platform with Alaya.bio's polymeric delivery system to develop new CAR-T product candidates.2
Renaud VAILLANT's leadership and extensive experience in the biotechnology industry position him as a key figure in the development of innovative cell therapies and drug delivery systems.
Highlights
I am thrilled to announce a strategic partnership between Alaya.bio and Lupagen. This new partnership will utilize Alaya.bio novel polymeric delivery platform for extracorporeal delivery using the Lupagen bedside system.
The two companies will collaborate to develop therapeutic gene delivery at the bedside enabling CAR-T cells to be generated at the patient's bedside and reinfused just a few hours after apheresis.
Together, we aim to set new standards in the cell and gene therapy industry which is seeking innovative delivery modalities to simplify high-cost and cumbersome ex vivo manufacturing processes.
Thank you, Nipon Das and David Peritt, for this scientific but also human collaboration we are now starting.
Cécile Bauche, Frederic Mourlane, Rachel Pacherie, Julie Bergalet, Céline Jaudoin, Alice Coillard, PhD, Marion LHUAIRE, Eva M., laurence leclere, Léa Dandan, Sarra Leschiutta, Anna Miodek, Ph.D.Marisol Sanz, Let's shift gears once again!
#CellTherapy #GeneTherapy #Biotech #HealthcareInnovation #Partnership #LifeSciences #CAR-T #Alayabio #Lupagen
